Press Release HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells Aug 25
Press Release HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Aug 14
Press Release HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 Jul 23